Dotmatics at Antibody Engineering & Therapeutics 2024
Dotmatics will exhibit at the Antibody Engineering & Therapeutics Conference from December 15-18, 2024, at the Marriott Marquis San Diego Marina (booth 313), featuring a presentation by Christian Olsen on December 16 about how Geneious Luma enhances therapeutic antibody engineering through adaptive workflows and data aggregation.
Join Dotmatics at the Antibody Engineering & Therapeutics Conference from December 15th - 18th at the Marriott Marquis San Diego Marina.
Visit booth 313 to meet the Dotmatics team and learn about Geneious Luma. Discover how Geneious Luma connects adaptive workflows and powerful data aggregation to streamline your research process.
Featured Presentation
- Christian Olsen, VP Strategy, Protein Therapeutics, Luma, will present "Revolutionizing Therapeutic Antibody Engineering with Geneious-Luma: A Path to Next-Gen Multispecific Antibodies" on December 16 at 1:45pm.
Event Details
- Dates: December 15 - 18, 2024
- Location: Marriott Marquis San Diego Marina, San Diego
- Booth: 313
- Time: 8:00am - 6:00pm
For more registration information, visit the event website.
Related
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.
Dotmatics Virtual Mini-Summit 2024
The Dotmatics Virtual Mini-Summit 2024 showcased the company's vision for revolutionizing R&D through modern solutions, featured a deep dive and live demo of the AI-enabled Dotmatics Luma platform with integrations to key scientific tools, and included a customer story highlighting the successful deployment and efficiency gains of Luma Lab Connect in pharmaceutical research.
New Dotmatics solution to streamline your antibody discovery process
Dotmatics' new Luma Antibody & Protein Engineering solution, built on the AI-native Geneious Luma platform and integrated with tools like GraphPad Prism, streamlines the complex antibody discovery and development process by unifying data, teams, and experimental phases within a single, collaborative environment to enhance biologics R&D productivity and overcome challenges of siloed data and rigid workflows.
Multispecific Antibodies: Engineering the Non-natural
The article discusses the challenges and innovations in designing multispecific antibodies (MsAbs)—complex, non-natural biologics aimed at treating difficult diseases beyond the scope of traditional monoclonal antibodies—highlighting the need for advanced, flexible, AI-powered in silico design tools, such as those developed by Dotmatics and BioGlyph, that use building-block-based approaches to enable researchers to engineer novel biologic formats beyond rigid, predefined structures.
Dotmatics at the Drug Discovery Innovation Forum 2024
Dotmatics will present their new SaaS product, Luma, at the 15th Annual Drug Discovery Innovation Forum on 4 September 2024 in Berlin, showcasing how Luma revolutionizes biologic therapeutic research by accelerating workflows and overcoming longstanding R&D productivity challenges.
Dotmatics Announces Investment in BioGlyph for Visualizing, Illustrating, and Modeling Multispecific Antibodies
Dotmatics has made a significant minority investment in BioGlyph, a biotech software startup specializing in proprietary technology to visually illustrate, register, and model multispecific antibodies (MsAbs), aiming to accelerate protein therapeutic development by addressing the growing need for advanced software tools that support complex antibody formats beyond traditional monoclonal antibodies, complementing Dotmatics' new scientific intelligence platform, Luma.